ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2011
The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Modulation of Stemness and Differentiation Regulators by Valproic Acid in Medulloblastoma Neurospheres.Cells · 2025Article
- Modulation of Stemness and Differentiation Regulators by Valproic Acid in Medulloblastoma Neurospheres.bioRxiv : the preprint server for biology · 2025Article
- Promising Chemotherapy for Malignant Pediatric Brain Tumor in Recent Biological Insights.Molecules (Basel, Switzerland) · 2022Review
- Neurotrophin Signaling in Medulloblastoma.Cancers · 2020Review
- Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.Molecular biology reports · 2020Article
- Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential.Frontiers in cell and developmental biology · 2020Review
- Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma.Frontiers in pharmacology · 2019Article
- BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors: Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells.Journal of molecular neuroscience : MN · 2016Article
- Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma.Oncotarget · 2016Article
- TrkB blockade in the hippocampus after training or retrieval impairs memory: protection from consolidation impairment by histone deacetylase inhibition.Journal of neural transmission (Vienna, Austria : 1996) · 2016Article
- Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.Journal of molecular neuroscience : MN · 2014Article
- The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.Molecular neurobiology · 2013Article
- Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHistone deacetylase inhibitors (HDACis) are a promising class of anticancer agents for the treatment of brain tumors. HDACis can increase the expression of brain-derived neurotrophic factor (BDNF) in brain cells. We have previously shown that BDNF reduces the viability of medulloblastoma cells. The aim of the present study was to examine the effect of the HDACi sodium butyrate (NaB) combined with human recombinant BDNF (hrBDNF), on the viability of human medulloblastoma cell lines.
methodsDAOY and ONS76 medulloblastoma cells were treated with NaB, hrBDNF, or NaB combined with hrBDNF. Cell viability was measured with the MTT assay.
resultsNaB combined with hrBDNF significantly reduced the viability of DAOY medulloblastoma cells. In ONS76 cells, NaB alone reduced viability, but the effect was not potentiated by hrBDNF.
conclusionThese findings provide early evidence for a rationale supporting further evaluation of HDACis and BDNF as a new combinatorial approach to inhibit the growth of medulloblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.